Search research articles
Contact Us
Filters
Showing results (131-140 of 159) with videos related to
Page
of 16
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 9, 2015
Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors
Didier Meulendijks, Ulrik N Lassen, Lillian L Siu, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 7, 2021
Phase II Trial of Symptom Screening With Targeted Early Palliative Care for Patients With Advanced Cancer
Camilla Zimmermann, Ashley Pope, Breffni Hannon, et al.
Cancer Discovery
|
February 23, 2024
Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
Eric Y Stutheit-Zhao, Enrique Sanz-Garcia, Zhihui Amy Liu, et al.
JCO Precision Oncology
|
February 9, 2022
Minimally Invasive Real-Time Detection of Actionable Mutations in Patients With Metastatic Solid Tumors Using Fine-Needle and Liquid Biopsies
Kyaw L Aung, Philippe L Bedard, Celeste Yu, et al.
Cancer
|
January 9, 2020
Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs
Aaron R Hansen, Kari Ala-Leppilampi, Chris McKillop, et al.
JAMA Oncology
|
April 6, 2023
Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial
Kevin J Harrington, Robert L Ferris, Maura Gillison, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 11, 2023
Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial
Abdulazeez Salawu, Ben X Wang, Ming Han, et al.
Clinical Colorectal Cancer
|
July 3, 2024
A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair-Proficient Colorectal or Pancreatic Cancer
Alberto Hernando-Calvo, Ming Han, Olubukola Ayodele, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 5, 2019
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Aurelien Marabelle, Dung T Le, Paolo A Ascierto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 22, 2025
INDUCE-3: A randomized Phase II/III study of first-line feladilimab plus pembrolizumab in patients with recurrent/metastatic head and neck squamous cell carcinoma
Danny Rischin, Aaron R Hansen, Ezra E W Cohen, et al.
Page
of 16
Search research articles
Search
Showing results (131-140 of 159) with videos related to
Sort By:
Page
of 16
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 9, 2015
Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors
Didier Meulendijks, Ulrik N Lassen, Lillian L Siu, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 7, 2021
Phase II Trial of Symptom Screening With Targeted Early Palliative Care for Patients With Advanced Cancer
Camilla Zimmermann, Ashley Pope, Breffni Hannon, et al.
Cancer Discovery
|
February 23, 2024
Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
Eric Y Stutheit-Zhao, Enrique Sanz-Garcia, Zhihui Amy Liu, et al.
JCO Precision Oncology
|
February 9, 2022
Minimally Invasive Real-Time Detection of Actionable Mutations in Patients With Metastatic Solid Tumors Using Fine-Needle and Liquid Biopsies
Kyaw L Aung, Philippe L Bedard, Celeste Yu, et al.
Cancer
|
January 9, 2020
Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs
Aaron R Hansen, Kari Ala-Leppilampi, Chris McKillop, et al.
JAMA Oncology
|
April 6, 2023
Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial
Kevin J Harrington, Robert L Ferris, Maura Gillison, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 11, 2023
Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial
Abdulazeez Salawu, Ben X Wang, Ming Han, et al.
Clinical Colorectal Cancer
|
July 3, 2024
A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair-Proficient Colorectal or Pancreatic Cancer
Alberto Hernando-Calvo, Ming Han, Olubukola Ayodele, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 5, 2019
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Aurelien Marabelle, Dung T Le, Paolo A Ascierto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 22, 2025
INDUCE-3: A randomized Phase II/III study of first-line feladilimab plus pembrolizumab in patients with recurrent/metastatic head and neck squamous cell carcinoma
Danny Rischin, Aaron R Hansen, Ezra E W Cohen, et al.
Page
of 16